EP0596059A1 - Procede de limitation, a l'aide de gaz nobles, de l'oxydation des produits chimiques pendant leur entreposage - Google Patents
Procede de limitation, a l'aide de gaz nobles, de l'oxydation des produits chimiques pendant leur entreposageInfo
- Publication number
- EP0596059A1 EP0596059A1 EP93908878A EP93908878A EP0596059A1 EP 0596059 A1 EP0596059 A1 EP 0596059A1 EP 93908878 A EP93908878 A EP 93908878A EP 93908878 A EP93908878 A EP 93908878A EP 0596059 A1 EP0596059 A1 EP 0596059A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- chemical
- oxidation
- nitrogen
- gases
- noble
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000126 substance Substances 0.000 title claims abstract description 89
- 229910052756 noble gas Inorganic materials 0.000 title claims abstract description 67
- 238000007254 oxidation reaction Methods 0.000 title claims abstract description 49
- 230000003647 oxidation Effects 0.000 title claims abstract description 44
- 238000003860 storage Methods 0.000 title claims abstract description 36
- 150000002835 noble gases Chemical class 0.000 title claims abstract description 33
- 238000000034 method Methods 0.000 title claims abstract description 30
- 238000002360 preparation method Methods 0.000 claims abstract description 48
- 239000000203 mixture Substances 0.000 claims abstract description 23
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 claims description 64
- 229910052786 argon Inorganic materials 0.000 claims description 37
- 229910052724 xenon Inorganic materials 0.000 claims description 17
- 229910052754 neon Inorganic materials 0.000 claims description 16
- 229910052743 krypton Inorganic materials 0.000 claims description 14
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 claims description 14
- GKAOGPIIYCISHV-UHFFFAOYSA-N neon atom Chemical compound [Ne] GKAOGPIIYCISHV-UHFFFAOYSA-N 0.000 claims description 13
- DNNSSWSSYDEUBZ-UHFFFAOYSA-N krypton atom Chemical compound [Kr] DNNSSWSSYDEUBZ-UHFFFAOYSA-N 0.000 claims description 11
- 239000008246 gaseous mixture Substances 0.000 claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 7
- 239000003153 chemical reaction reagent Substances 0.000 claims description 3
- 239000003054 catalyst Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000011541 reaction mixture Substances 0.000 claims 1
- 239000012048 reactive intermediate Substances 0.000 claims 1
- 239000007789 gas Substances 0.000 abstract description 41
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 98
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 57
- 229910052757 nitrogen Inorganic materials 0.000 description 51
- 239000000243 solution Substances 0.000 description 33
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 32
- 229910052760 oxygen Inorganic materials 0.000 description 32
- 239000001301 oxygen Substances 0.000 description 32
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 26
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 26
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 26
- 229960001285 quercetin Drugs 0.000 description 26
- 235000005875 quercetin Nutrition 0.000 description 26
- 239000003570 air Substances 0.000 description 25
- 239000012298 atmosphere Substances 0.000 description 17
- 230000000694 effects Effects 0.000 description 13
- 210000002966 serum Anatomy 0.000 description 12
- 239000007983 Tris buffer Substances 0.000 description 11
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 11
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 11
- 238000002835 absorbance Methods 0.000 description 10
- UYYRDZGZGNYVBA-VPXCCNNISA-N (2s,3r,4s,5r,6r)-2-[2-chloro-4-[3-(3-chloro-4-hydroxyphenyl)-1,1-dioxo-2,1$l^{6}-benzoxathiol-3-yl]phenoxy]-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(C2(C3=CC=CC=C3S(=O)(=O)O2)C=2C=C(Cl)C(O)=CC=2)C=C1Cl UYYRDZGZGNYVBA-VPXCCNNISA-N 0.000 description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 8
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 8
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 8
- 229910052782 aluminium Inorganic materials 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 229910001868 water Inorganic materials 0.000 description 8
- 230000006872 improvement Effects 0.000 description 7
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000012546 transfer Methods 0.000 description 6
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 229920001971 elastomer Polymers 0.000 description 5
- 229920001296 polysiloxane Polymers 0.000 description 5
- 238000010926 purge Methods 0.000 description 5
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 4
- 239000002211 L-ascorbic acid Substances 0.000 description 4
- 235000000069 L-ascorbic acid Nutrition 0.000 description 4
- 229960005070 ascorbic acid Drugs 0.000 description 4
- 239000001272 nitrous oxide Substances 0.000 description 4
- 229960003471 retinol Drugs 0.000 description 4
- 235000020944 retinol Nutrition 0.000 description 4
- 239000011607 retinol Substances 0.000 description 4
- 238000005070 sampling Methods 0.000 description 4
- SKYZYDSNJIOXRL-BTQNPOSSSA-N (6ar)-6-methyl-5,6,6a,7-tetrahydro-4h-dibenzo[de,g]quinoline-10,11-diol;hydrochloride Chemical compound Cl.C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 SKYZYDSNJIOXRL-BTQNPOSSSA-N 0.000 description 3
- 229930182837 (R)-adrenaline Natural products 0.000 description 3
- 101150094949 APRT gene Proteins 0.000 description 3
- 102100025490 Slit homolog 1 protein Human genes 0.000 description 3
- 101710123186 Slit homolog 1 protein Proteins 0.000 description 3
- 229960003990 apomorphine hydrochloride Drugs 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000001569 carbon dioxide Substances 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229960005139 epinephrine Drugs 0.000 description 3
- 239000011888 foil Substances 0.000 description 3
- 239000001307 helium Substances 0.000 description 3
- 229910052734 helium Inorganic materials 0.000 description 3
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 229960004715 morphine sulfate Drugs 0.000 description 3
- 238000010525 oxidative degradation reaction Methods 0.000 description 3
- 230000001590 oxidative effect Effects 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 229960001005 tuberculin Drugs 0.000 description 3
- -1 vinylidene halide compounds Chemical class 0.000 description 3
- 229920002274 Nalgene Polymers 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 229960004046 apomorphine Drugs 0.000 description 2
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 2
- UBAZGMLMVVQSCD-UHFFFAOYSA-N carbon dioxide;molecular oxygen Chemical compound O=O.O=C=O UBAZGMLMVVQSCD-UHFFFAOYSA-N 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- XMEVHPAGJVLHIG-FMZCEJRJSA-N chembl454950 Chemical compound [Cl-].C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H]([NH+](C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O XMEVHPAGJVLHIG-FMZCEJRJSA-N 0.000 description 2
- 230000003412 degenerative effect Effects 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 229960003072 epinephrine hydrochloride Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 239000011261 inert gas Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- VUZPPFZMUPKLLV-UHFFFAOYSA-N methane;hydrate Chemical compound C.O VUZPPFZMUPKLLV-UHFFFAOYSA-N 0.000 description 2
- GRVOTVYEFDAHCL-RTSZDRIGSA-N morphine sulfate pentahydrate Chemical compound O.O.O.O.O.OS(O)(=O)=O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O GRVOTVYEFDAHCL-RTSZDRIGSA-N 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 229910052704 radon Inorganic materials 0.000 description 2
- SYUHGPGVQRZVTB-UHFFFAOYSA-N radon atom Chemical compound [Rn] SYUHGPGVQRZVTB-UHFFFAOYSA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 229960004989 tetracycline hydrochloride Drugs 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- WVVSZNPYNCNODU-CJBNDPTMSA-N Ergometrine Natural products C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@@H](CO)C)C2)=C3C2=CNC3=C1 WVVSZNPYNCNODU-CJBNDPTMSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WVVSZNPYNCNODU-XTQGRXLLSA-N Lysergic acid propanolamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@H](CO)C)C2)=C3C2=CNC3=C1 WVVSZNPYNCNODU-XTQGRXLLSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 239000012080 ambient air Substances 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- WZSUOQDIYKMPMT-UHFFFAOYSA-N argon krypton Chemical compound [Ar].[Kr] WZSUOQDIYKMPMT-UHFFFAOYSA-N 0.000 description 1
- IXMPXTJYLZVFBW-UHFFFAOYSA-N argon neon Chemical compound [Ne].[Ne].[Ar] IXMPXTJYLZVFBW-UHFFFAOYSA-N 0.000 description 1
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000000973 cosmetic coloring agent Substances 0.000 description 1
- WQABCVAJNWAXTE-UHFFFAOYSA-N dimercaprol Chemical compound OCC(S)CS WQABCVAJNWAXTE-UHFFFAOYSA-N 0.000 description 1
- 229960001051 dimercaprol Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229960001405 ergometrine Drugs 0.000 description 1
- OFKDAAIKGIBASY-VFGNJEKYSA-N ergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2C(C3=CC=CC4=NC=C([C]34)C2)=C1)C)C1=CC=CC=C1 OFKDAAIKGIBASY-VFGNJEKYSA-N 0.000 description 1
- 229960004943 ergotamine Drugs 0.000 description 1
- XCGSFFUVFURLIX-UHFFFAOYSA-N ergotaminine Natural products C1=C(C=2C=CC=C3NC=C(C=23)C2)C2N(C)CC1C(=O)NC(C(N12)=O)(C)OC1(O)C1CCCN1C(=O)C2CC1=CC=CC=C1 XCGSFFUVFURLIX-UHFFFAOYSA-N 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- SLSBUGNNRDXZJZ-UHFFFAOYSA-N krypton neon Chemical compound [Ne].[Kr] SLSBUGNNRDXZJZ-UHFFFAOYSA-N 0.000 description 1
- PDEXVOWZLSWEJB-UHFFFAOYSA-N krypton xenon Chemical compound [Kr].[Xe] PDEXVOWZLSWEJB-UHFFFAOYSA-N 0.000 description 1
- 238000012886 linear function Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000008155 medical solution Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229960002895 phenylbutazone Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003243 quercetin Chemical class 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K15/00—Anti-oxidant compositions; Compositions inhibiting chemical change
- C09K15/02—Anti-oxidant compositions; Compositions inhibiting chemical change containing inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
Definitions
- the present invention provides a method of controlling the oxidation of chemicals during storage using a noble gas, a mixture of noble gases or a gaseous mixture containing at least one noble gas. Description of the Background;
- French Patent 1,339,669 discloses that argon may be used to render oxidizable chemicals of biological origin inert to oxidation because it desorbs oxygen.
- this patent specifically states that oxygen must be removed for any inhibitory effect upon oxidation to be observed.
- U.S. 3,143,471 a method is described whereby dry argon is used in the packaging of lyophilized pharmaceuticals, generally, wherein the sole object of the process is the displacement of water and oxygen from the packaging space.
- inert or non-reactive atmospheres which can be either nitrogen or argon are recommended for packaging or storaging chemicals or chemical preparations such as oils (JP 3200568), polyacrylic acids (U.S. 4,622,425), N,N-dialkylaminopropyl compounds (JP 63077848), alpha-cyano-acrylic ester (JP 52097913, 85007609), vinylidene halide compounds (U.S. 3,957,892), sodium products (FR 2,261,518), chemical propellants (DE 3,007,712), medical solutions (U.S. 4,664,256), silicon wafers (U.S.
- HEET CH 589403 AT 7505161, DE 2,437,812, IT 1040412, JP 51035583, JP 83040521
- developer sheets JP 3057689, U.S. 5,064,070
- photosensitive donor media U.S. 4,965,165
- agricultural antiseptic suspensions JP 2104502
- preparation or synthesis of chemicals under generally inert atmospheres in which the use of either nitrogen or argon without distinction is recommended include, as examples, purification and stabilization of catechol-containing proteins (U.S. 4,496,397), preparation of cosmetic dyes (U.S. 4,314,810), synthesis of peptides (FR 1,454,653, AU 6565762), synthesis of antibiotics (JP 58039650, JP 89039416).
- an object of the present invention to provide a method for enhancing the stability of chemicals or chemical preparations during storage thereof.
- a method of controlling the oxidation of chemicals or chemical preparations during at least a portion of storage thereof by contacting the same with a noble gas, a mixture of noble gases or a gaseous mixture containing at least one noble gas.
- Figure 2 illustrates the absorptivity of Quercetin under different atmospheres of oxygen, nitrogen, argon, krypton and xenon at 25°C.
- Figure 3 illustrates the absorptivity of Quercetin under different atmospheres of oxygen, nitrogen, argon, neon and air at 25°C.
- Figure 4 illustrates the absorptivity of morphine sulfate under different atmospheres of oxygen, nitrogen and argon after 31 days of storage at ambient temperature.
- Figure 5 illustrates the absorptivity of apomorphine hydrochloride under different atmospheres of oxygen, nitrogen and argon after 31 days of storage at ambient temperature.
- Figure 6 illustrates the absorptivity of apomorphine hydrochloride under different atmospheres of oxygen, nitrogen and argon after 31 days of storage at ambient temperature.
- Figure 7 illustrates the absorptivity of apomorphine hydrochloride under different atmospheres of nitrogen and argon after 31 days at ambient temperature.
- Figure 8 illustrates the absorptivity of epinephrine hydrochloride under different atmospheres of nitrogen, argon, krypton and xenon after 31 days at ambient temperature.
- Figure 9 illustrates the absorptivity of epinephrine hydrochloride under different atmospheres of nitrogen and xenon for 31 days and three and one-half months, respectively, for each.
- Figure 10 illustrates the absorptivity of L-ascorbic acid under different atmospheres of oxygen and nitrogen.
- HEET Figure 11 illustrates the absorptivity of L-ascorbic acid under different atmospheres of nitrogen, argon, krypton, xenon and neon after 30 days at ambient temperature.
- Figure 12 illustrates the absorptivity of retinol under different atmospheres of nitrogen, argon, krypton and xenon after 3 months at ambient temperature in darkness.
- Figure 13 illustrates the absorptivity of tetracycline hydrochloride under different atmospheres of air and nitrogen for 33 days and four months each, respectively.
- Figure 14 illustrates the absorptivity of tetracycline hydrochloride under different atmospheres of air and neon for 33 days and four months each, respectively.
- the present invention it has been surprisingly discovered that it is possible to directly affect the rate of oxidation of chemicals or chemical preparations. That is, in accordance with the present invention it has been discovered that certain gases can directly affect the oxidation rate of chemicals and not merely slow oxidation only as function of physical and inert displacement of oxygen.
- the present invention is effected by contacting the chemicals or chemical preparations during at least a portion of storage thereof to a noble gas, a mixture of noble gases or a gaseous mixture containing at least one noble gas.
- the present invention is predicated upon the discovery that by contacting chemicals or chemical preparations with an atmosphere containing a noble gas, a mixture of noble or a gaseous mixture containing at least one noble gas during at least a portion of storage it is possible to effectively control oxidation reactions which degrade such compounds or preparations.
- noble gases are surprisingly more effective than nitrogen or other inert or non-reactive gases in actually and effectively controlling the oxidation of chemical compounds or chemical preparations.
- the present invention is predicated upon a, heretofore, undiscovered property of noble gases in interfering with oxidation reactions of chemicals and chemical preparations during storage.
- a method is also provided for inhibiting oxidation of chemicals or chemical preparations. Further, the present invention may be advantageously used at any time during storage of chemicals or chemical preparations.
- noble gases possess a surprising ability to control, and specifically inhibit oxidation to a degree quite superior to that exhibited by nitrogen.
- the use of noble gases instead of nitrogen confers additional stability to stored chemical products or chemical preparations.
- the term "noble gas” generally includes argon, xenon, krypton or neon. While other noble gases, such as radon or helium may be used, the use of radon is generally impractical as it is dangerously reactive. While helium confers a positive benefit, and less than the other noble gases, and may be freely admixed with any other noble gas to advantage, its use is limited by its poor solubility in aqueous solutions and its tendency to dissipate by penetrating packaging materials. However, it is reiterated that the present invention is predicated upon the surprising discovery of the ability of all of the noble gases to control the oxidation of chemicals or chemical preparations.
- atmospheres containing noble gases in quantities greater than those normally found in ambient air significantly improve storage characteristics and shelf-life of chemicals or chemical preparations. Further, the effective improvement is of wide practical utility and clear economic benefit.
- any amount of noble gas above that found in normal atmospheric air may be used to advantage in the present invention.
- argon is generally accepted as being present in the atmosphere in the amount of about 0.934% by volume.
- neon, krypton and xenon are normally present in the atmosphere in amounts of 1.82 X 10 ⁇ 3 , 1.14 X 10" 3 and 8.7 X 10 ⁇ 6 , respectively, by % volume.
- Advanced Inorganic Chemistry , Cotton and Wilkinson (Third Edition, Wiley).
- any amount of noble gas may be used which is greater than that found in atmospheric air.
- this amount is preferably at least 1% by volume, and is more preferably in excess of 1% by volume for argon.
- krypton and xenon amounts generally used are at least 0.05% each, by volume. However, it is generally preferred that the amounts of neon, krypton and xenon used be greater than about 0.1% each, by volume.
- any gas, mixtures of gases, liquid or mixtures of liquids may be used in accordance with the present invention as long as they contain an amount of at least one noble gas as described above. Preferably, however, they contain at least the preferred amounts noted above.
- -lo ⁇ in addition to noble gases or noble gas mixtures, any gaseous mixture may be used in accordance with the present invention which contains at least one noble gas.
- unpurified mixtures of gases from air separation plants such as about 90;10 Kr;Xe, and about 1:1 He:Ne, for example.
- atmospheric pressures of from less than one to greater than 1 may be used.
- it has been found acceptable to use quite low pressures such as those near vacuum conditions, such as, for example about 10 ⁇ 9 torr to very high pressures of about 100 atm or greater.
- atmospheres ranging from about 0.5 to 20 atm, preferably about from 1 to 10 atm.
- the effective stabilization is observed even when the noble gas-containing atmosphere contains other inert gases, such as nitrogen.
- the effect appears to be directly related to the actual quantitative amount of noble gas present and available to the reactive sites on the subject chemical or chemical preparation.
- the effect thereof is observed even when the noble gas- containing atmosphere contains other reactive gases including oxygen, carbon dioxide, water, or nitrous oxide.
- diminution of the antioxidative effect is seen in direct consequence of the inclusion of these oxygen-containing gases, and is a direct, linear function of their concentration.
- the maximum antioxidative effect of argon is seen when argon is present as 100% of the superimposed atmosphere (and effectiveness may be increased by increasing the relative molar concentration of argon by increasing pressure)
- the minimal effect is observed when argon is present in concentrations only slightly greater than its normal concentration in air (0.1% by volume) admixed with any of oxygen, carbon dioxide, water or nitrous oxide.
- the method is most effective when noble gas concentrations in excess of 50% of the atmosphere are used, preferably in excess of 90%, preferably in excess of 95% of the atmosphere.
- the improvement of the present invention is generally noted for noble gas-containing atmospheres which might also contain other gases, except that reactive components of these other gases may promote oxidation and mask the desired effect.
- reactive components of these other gases may promote oxidation and mask the desired effect.
- complex mixtures of gases which include noble gases will promote oxidation less than similar mixtures which do not contain noble gases.
- the antioxidation potential of the noble gases is of the order of:
- the observed effectiveness of the noble gases is partially, but not wholly dependent, upon their relative solubility in the chemicals or chemical preparations treated.
- the observed effectiveness of the noble gases is partially, but not wholly dependent, upon their relative ability to desorb oxygen or water from subject chemical preparations.
- the effects of the noble gases may be either ameliorated or potentiated by the admixture of other gases thereto.
- the observed improvement in accordance with the present invention is notable for noble-containing solutions, either aqueous or non-aqueous, when applied to retard oxidation, in a manner similar to the use of atmospheres.
- the optimal method consists of saturating the solution with the desired gas by sparging or superimposition or by use of pressure or through introduction of cryogenic liquid.
- cryogenic liquid composed of or containing noble gases, such as cryogenic argon
- cryogenic nitrogen inert
- carbon dioxide reactive
- the quantative improvement in sh ⁇ lf-life may be observed is several times that observed with nitrogen, with the improvement being 25 to 100% being obtained with ease.
- the preferred method of use of the present invention is to store the chemicals or chemical preparations under an atmosphere containing a noble gas, mixture of noble gases or gaseous mixture containing at least one noble gas which gases exhibit the best effect, and additionally storing in gas- and moisture-impermeable containers, storing at low temperatures and storing in containers which block incident light or other radiation.
- any chemical or chemical preparation which is susceptible to oxidative degradation may be protected by the present invention.
- such chemicals or preparations may include chemical reagents, deoxygenated solvents, reducing agents and catalysts.
- storage temperatures of from about -20°C to about 60°C, preferably from about -10°C to about 30°C, may be used.
- the progress of the oxidations were monitored either by ultraviolet/visible spectrophoto etry, or by spectrocolorimetry, or by direct visual observation, or by the production of a detectable product (detected chemically, or by gas chromatography/mass spectrometry, or by thin layer chromatography) , or by other standard means, depending upon the nature of the chemical oxidation to be measured.
- the atmospheres tested include argon, xenon, krypton, neon, helium, nitrogen, oxygen, air, carbon dioxide, nitrous oxide, and decile mixtures of each possible pair and triad, and certain representative other combinations. Tests were conducted in the presence or absence of water vapor, light, temperature, and under differing conditions of concentration and pH. In certain cases, atmospheres were changed after a certain time period in order to observe changing effects. For instance, it was observed in every case of noble gas retardation of oxidation that replacing the noble gas-containing atmosphere with air or oxygen immediately produced the maximum degenerative effect, and that replacing the effective noble gas-containing atmosphere with nitrogen immediately ended the observed retardation effect.
- nitrous oxide, carbon dioxide, air and oxygen produced degenerative oxidative effects, nitrogen diminished these effects to the extent that oxygen was excluded from the reaction, and the noble gases diminished the effect further. This further effect was evident even when oxygen was added in amounts greater than could be accounted for by the different desorptive ability of the various noble gases and nitrogen, and in amounts greater than could be accounted for by different solubilities of the gases in solution.
- Vitamin Bl Specific Examples: Example 1: Quercetin
- the 2 vials are stored at room temperature over the week-end (unprotected from light) .
- Vial C/0 2 (see 09/13/91 QUERC01.WP) has turned orange, while vial C/N 2 is still yellow. No further color changes are observed on the following days. 2. Full Range Scans (900-190 nm) : 09/16/91
- Purge cuvet 1 with 0 2 on-line for 30 s.
- Purge cuvet 2 with N 2 on-line for 30 s.
- Blank cuvet acrylic cuvet filled with 3 ml D.I. H 2 0. Using a 3cc syringe previously purged with 0 , transfer 3 ml from vial C/0 2 into cuvet 1.
- Blank cuvet acrylic cuvet filled with 2.5 ml of TRIS buffer pH 9.0.
- Label and stopper 5 acrylic cuvets with blue silicone (gas-tight) .
- Label QT4Gn, where:
- the gassing order is still: N 2 , Ar, Kr, Xe and finally 0 2 .
- Blank cuvet acrylic cuvet filled with 2.5 ml of TRIS buffer pH 9.0.
- the 100 ⁇ g/ml quercetin solution is stored in refrigerator (serum vial being wrapped in aluminum foil to prevent light degradation) .
- Blank cuvet acrylic cuvet filled with 2.5 ml of TRIS buffer pH 9.0.
- Stopper 1 acrylic cuvet with blue silicone (gas- tight) . Flush cuvet with on-line nitrogen for 1 min. Using a 3cc B-D syringe (purged with N 2 ) , transfer 2.5 ml of solution C into the cuvet. Run a full range scan (900-190 nm) of sample cuvet vs blank.
- Bubble 3x3Occ of the appropriate gas through each vial Inject an additional lOcc of the appropriate gas to leave vial under positive pressure.
- Gassing is done in the following order: N , Ne, Ar, Kr, Xe, Air, and finally 0 2 .
- the lOcc vials are left on the lab bench at room temperature.
- the vials are regularly observed visually for color changes.
- Blank cuvet acrylic cuvet filled with 2.5 ml of TRIS buffer pH 9.0.
- Figure 1 shows that following ABS at 400 nm will reveal the progressive oxidation of the molecule.
- Figure 2 shows that nitrogen retards oxidation poorly compared to argon, and krypton and xenon inhibit oxidation much better than argon.
- Figure 3 shows a replicate (differences between Figs. 2 and 3 are due to different start times) which shows additionally that neon inhibits about as well as argon. Since the solubilities of argon and neon are very different yet that of neon and nitrogen very similar, the activity is clearly at least partly independent of solubility.
- Figure 9 demonstrates the same for nitrogen and xenon in comparing degree of oxidation after 1 month versus 3 1/2 months of storage.
- Example 5 L-Ascorbic acid
- Figure 10 shows the oxidative abscissal absorbance shift.
- Figure 11 shows that preservation is in the order Kr>Ar>Ne>N 2 >Xe after 30 days.
- Figure 12 shows the very great improvement obtained in storing retinol under noble gases compared with nitrogen.
- diminution of absorbance in the 320-324 nm range is indicative of oxidation.
- Figure 13 compares oxidation over this time period in an oxygen atmosphere versus a nitrogen atmosphere. Comparing Figure 13 with Figure 14 demonstrates clearly that a neon atmosphere provides greater protection.
- the present invention is surprisingly effective in controlling oxidation of chemicals or chemical preparations or both in storage.
- binary mixtures such as argon-krypton, krypton-neon, xenon-krypton or argon-neon, for example, ternary mixtures or even quaternary mixtures of noble gases may be used.
- deoxygenated air generally means an oxygen content of less than about 15%, better yet less than about 10%, and more preferably less than about 5% by volume.
- the gases or gas mixture may be introduced either in gaseous or liquid form. If liquid form, the noble gases may be used neat or dissolved in a suitable liquid gas such as liquid nitrogen.
- the advantage of the present invention may be obtained even if the chemicals or chemical preparations are contacted with the gases of the present invention for only a portion of the storage period. However, it is generally preferably to effect such contact throughout the entire storage period.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Inorganic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Procédé de limitation de l'oxydation d'un produit chimique ou d'une préparation chimique pendant son entreposage. Il consiste, pendant au moins une partie de la durée d'entreposage, à mettre les produits ou préparations chimiques en contact avec au moins un gaz noble, un mélange de gaz nobles ou un mélange gazeux renfermant au moins un gaz noble.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02012889A EP1258522A2 (fr) | 1992-04-03 | 1993-03-31 | Procede de limitation, a l'aide de gaz nobles, de l'oxydation des produits chimiques pendant leur entreposage |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US86305692A | 1992-04-03 | 1992-04-03 | |
US863056 | 1992-04-03 | ||
PCT/EP1993/000802 WO1993020168A1 (fr) | 1992-04-03 | 1993-03-31 | Procede de limitation, a l'aide de gaz nobles, de l'oxydation des produits chimiques pendant leur entreposage |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP02012889A Division EP1258522A2 (fr) | 1992-04-03 | 1993-03-31 | Procede de limitation, a l'aide de gaz nobles, de l'oxydation des produits chimiques pendant leur entreposage |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0596059A1 true EP0596059A1 (fr) | 1994-05-11 |
Family
ID=25340133
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP93908878A Withdrawn EP0596059A1 (fr) | 1992-04-03 | 1993-03-31 | Procede de limitation, a l'aide de gaz nobles, de l'oxydation des produits chimiques pendant leur entreposage |
EP02012889A Withdrawn EP1258522A2 (fr) | 1992-04-03 | 1993-03-31 | Procede de limitation, a l'aide de gaz nobles, de l'oxydation des produits chimiques pendant leur entreposage |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP02012889A Withdrawn EP1258522A2 (fr) | 1992-04-03 | 1993-03-31 | Procede de limitation, a l'aide de gaz nobles, de l'oxydation des produits chimiques pendant leur entreposage |
Country Status (5)
Country | Link |
---|---|
EP (2) | EP0596059A1 (fr) |
JP (1) | JPH06507940A (fr) |
AU (1) | AU3950493A (fr) |
CA (1) | CA2102779A1 (fr) |
WO (1) | WO1993020168A1 (fr) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6320069B1 (en) * | 1996-07-02 | 2001-11-20 | Toray Industries, Inc. | Production of optically active ketone |
IT1301771B1 (it) * | 1998-06-22 | 2000-07-07 | Laffon Spa | Procedimento di riempimento meccanico di un contenitore per prodotticosmetici. |
WO2011075391A1 (fr) * | 2009-12-15 | 2011-06-23 | Schering Corporation | Mode de préparation d'acadésine |
US9119876B1 (en) | 2015-03-13 | 2015-09-01 | Par Pharmaceutical, Inc. | Epinephrine formulations |
US20170189352A1 (en) | 2015-03-13 | 2017-07-06 | Par Pharmaceutical, Inc. | Epinephrine formulations |
WO2019183416A1 (fr) | 2018-03-23 | 2019-09-26 | Nevakar Inc. | Compositions et récipients d'épinéphrine |
US20200197355A1 (en) * | 2018-12-20 | 2020-06-25 | Public Joint Stock Company "Scientific Industrial Centre "Borshchahivskiy Chemical-Pharmaceutical Pl | Methods, compositions and containers for reducing solid form quercetin degradation and 2-(3,4-dihydroxybenzoyloxy)-4,6-dihydroxybenzoic acid toxic byproducts thereof |
US20200197354A1 (en) * | 2018-12-20 | 2020-06-25 | Public Joint Stock Company "Scientific Industrial Centre "Borshchahivskiy Chemical- Pharmaceutical P | Methods, compositions and containers for reducing solid form quercetin degradation and 2,4,6-trihydroxybenzoic acid toxic byproduct thereof |
US11156623B2 (en) | 2018-12-20 | 2021-10-26 | Public Joint Stock Company “Scientific Industrial Centre Borshchahivskiy Chemical-Pharmaceutical Plant” | Methods of monitoring safety of quercetin compositions |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR1339669A (fr) * | 1962-08-31 | 1963-10-11 | Air Liquide | Procédé de stabilisation de produits altérables à l'air |
US4328249A (en) * | 1981-01-30 | 1982-05-04 | Life Savers, Inc. | Method for treating gum base to improve shelf-life without need for antioxidants |
DE3912153C1 (en) * | 1989-04-13 | 1990-08-02 | Christoph V. Dr.Rer.Nat. Stein | Preventing deterioration of solns. by oxidn. - by feeding solns. in containers from which air has been expelled by injected protective gas |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS548840A (en) * | 1977-06-22 | 1979-01-23 | Suwa Seikosha Kk | Time keeper using cell |
JPS56161841A (en) * | 1980-05-19 | 1981-12-12 | Mitsubishi Petrochem Co Ltd | Manufacture of composite oxide catalyst |
DE3341513A1 (de) * | 1983-11-17 | 1985-06-20 | Hans 5462 Bad Hönningen Ziegeler | Verfahren fuer korrosionsschutz und konservierung von sauerstoff und mit sauerstoff oxidierenden gegenstaenden, aller art und groesse |
NZ235528A (en) * | 1989-10-05 | 1992-12-23 | Air Liquide | Preservation of fresh edible plant products using an atmosphere containing nitrogen monoxide and/or argon |
US5021251A (en) * | 1990-07-23 | 1991-06-04 | Borden, Inc. | Process for preserving lemon juice utilizating a non-sulfite preservative |
TW284788B (fr) * | 1991-05-28 | 1996-09-01 | L Air Liquide Soliete And Nyme Dour L Expl Des Proce | |
KR950006897B1 (ko) * | 1991-07-04 | 1995-06-26 | 롱-쁠랑 쉬미 | 포화 탄화수소의 암모산화 방법 |
-
1993
- 1993-03-31 AU AU39504/93A patent/AU3950493A/en not_active Abandoned
- 1993-03-31 WO PCT/EP1993/000802 patent/WO1993020168A1/fr not_active Application Discontinuation
- 1993-03-31 CA CA002102779A patent/CA2102779A1/fr not_active Abandoned
- 1993-03-31 EP EP93908878A patent/EP0596059A1/fr not_active Withdrawn
- 1993-03-31 EP EP02012889A patent/EP1258522A2/fr not_active Withdrawn
- 1993-03-31 JP JP5517101A patent/JPH06507940A/ja active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR1339669A (fr) * | 1962-08-31 | 1963-10-11 | Air Liquide | Procédé de stabilisation de produits altérables à l'air |
US4328249A (en) * | 1981-01-30 | 1982-05-04 | Life Savers, Inc. | Method for treating gum base to improve shelf-life without need for antioxidants |
DE3912153C1 (en) * | 1989-04-13 | 1990-08-02 | Christoph V. Dr.Rer.Nat. Stein | Preventing deterioration of solns. by oxidn. - by feeding solns. in containers from which air has been expelled by injected protective gas |
Non-Patent Citations (1)
Title |
---|
See also references of WO9320168A1 * |
Also Published As
Publication number | Publication date |
---|---|
JPH06507940A (ja) | 1994-09-08 |
WO1993020168A1 (fr) | 1993-10-14 |
CA2102779A1 (fr) | 1993-10-04 |
AU3950493A (en) | 1993-11-08 |
EP1258522A2 (fr) | 2002-11-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Davison et al. | Mechanism of the inhibition of catalase by ascorbate. Roles of active oxygen species, copper and semidehydroascorbate. | |
EP0596059A1 (fr) | Procede de limitation, a l'aide de gaz nobles, de l'oxydation des produits chimiques pendant leur entreposage | |
Burton et al. | β-Carotene: an unusual type of lipid antioxidant | |
Davies et al. | Direct detection of a globin-derived radical in leghaemoglobin treated with peroxides | |
US5051353A (en) | Preservation and restoration of hemoglobin in blood substitutes | |
Osaki et al. | Kinetic Studies of Ferrous Ion Oxidation with Crystalline Human Ferroxidase: II. RATE CONSTANTS AT VARIOUS STEPS AND FORMATION OF A POSSIBLE ENZYME-SUBSTRATE COMPLEX | |
US5654164A (en) | Method and device for reducing oxygen with a reduced oxidase with color formation | |
US4236633A (en) | Process for storage | |
US5804401A (en) | Device for detecting oxygen with oxidase | |
US5328823A (en) | Enzyme-based biosensors for detecting noble gases | |
Notari et al. | Hydroxamic acids I: Factors affecting the stability of the hydroxamic acid-iron complex | |
US5707842A (en) | Method for regulating enzyme activities by noble gases | |
Hogg et al. | The reaction between nitric oxide and α-tocopherol: a reappraisal | |
EP0204616A1 (fr) | Compositions utiles pour détecter la présence d'oxygène, procédé de préparation de ces compositions et détecteurs d'oxygène les comportant | |
Amiconi et al. | Selective Oxidation of Methionine β (55) D6 at the α1β1 Interface in Hemoglobin Completely Destabilizes the T-state | |
Stratton et al. | The reduction of methemoglobin levels by antioxidants | |
Mendenhall | Stability of parenterals | |
US5382525A (en) | Method of effecting increased performance of diagnostic enzyme reaction systems using noble gases | |
Ewing | Synergistic Damage from H2 O2 and OH Radicals in Irradiated Cells | |
Ware | Nitrogenase of Klebsiella pneumoniae: interaction with viologen dyes as measured by acetylene reduction | |
Berg et al. | Glucose oxidase as a pharmaceutical antioxidant | |
Manabe et al. | Kinetic studies on the aerobic oxidation of reduced human ceruloplasmin | |
Thomas et al. | Studies of the reactivity of HO2O2− with unsaturated hydroperoxides in ethanolic solutions | |
Lambeir et al. | The formation and decay of the oxyferrous forms of the cytochromes P-450 isolated from Rhizobium japonicum. Rapid spectral scan and stopped flow studies | |
Khmelnitsky et al. | Detergentless microemulsions as media for enzymatic reactions: Catalytic properties of laccase in the ternary system hexane-2-propanol-water |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19931108 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): CH DE ES FR GB IT LI |
|
17Q | First examination report despatched |
Effective date: 19951004 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: L'AIR LIQUIDE, S.A. A DIRECTOIRE ET CONSEIL DE SUR |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
18W | Application withdrawn |
Effective date: 20021230 |